about
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer.11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.Molecular Imaging and Precision Medicine in Prostate Cancer.First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection.Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography.11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.Therapy assessment in prostate cancer using choline and PSMA PET/CT.Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.New aspects of molecular imaging in prostate cancer.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study.Restaging clear cell renal carcinoma with 18F-FDG PET/CT.11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.A new type of prostate cancer imaging. Will 64CuCl2 PET/CT flourish or vanish?11C-choline PET/CT for restaging of bladder cancer.Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings.11C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard.(68)Ga-PSMA PET/CT in prostate cancer.The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence.68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.Current application and future perspectives of PSMA PET imaging in prostate cancer.Detection of Sarcomatoid Lung Metastasis With 68GA-PSMA PET/CT in a Patient With Prostate Cancer.(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer.(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.Preoperative Staging With C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate CancerImaging of Prostate Cancer Using C-Choline PET/Computed TomographyGa-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategyIncidental Detection of Basaloid Thymic Carcinoma With Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate CancerOligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row
P50
Q38589076-EEBFCE22-F7BD-4B2A-ACEB-D758AB006D55Q38970106-2F147249-59EA-4952-B860-E94CD41817B3Q38970109-B09DBB76-2715-48EF-BA0A-1743540A4112Q39013373-1A8A84A8-28F2-4A7D-A85D-EAC8C18BC99FQ39114508-BB0719C7-72F0-456F-A925-F697659B6536Q39166080-AE320285-C7D5-455E-BB7B-B38EE9BF7945Q39293042-3573FBBD-A686-4D9A-A075-270833AE17A1Q39328036-BC2FE6F2-EA24-4C01-8A4A-B114947E7E61Q39369144-66923B90-FF21-4E39-9642-FA316E275967Q39437137-F7AB57E4-74E3-44E0-9DBD-513DB294DA56Q39699773-625B26EB-E43F-4942-8F59-C40FAC78EBC6Q40188618-D2E2E6AB-AF5E-4D01-B1B6-3A10315B580DQ43576937-6F0A6C64-177E-429E-93C0-23773CC63E2CQ45979396-2E1FB469-F5F6-4D82-A859-DF9D08404CF4Q46084522-C7312648-B379-4E2D-9F05-D8BCB56DC9B3Q46225464-5CA00D75-CEB2-4444-AFD3-87A3BF3A0E09Q46237568-4F3BB9D1-5320-4B56-9ED1-2BEA875D9E41Q46434290-358E299C-EF03-4E07-94B2-8715C05C5451Q46476500-6D3A6638-1E43-41A7-89BD-819A60909AB0Q46719854-4622ADFE-2232-44BE-8A4D-CF6F39B4F121Q47754426-1C69D73F-2BCB-4F60-8CD1-2CBB0F0AA43EQ47794903-A7A251DE-66B9-4BC8-B2AB-F56F7E2B4EF7Q48139886-865FE069-3A7B-49A6-8B0B-C346F79DD222Q48205881-5FBCD727-7558-4929-B2FB-2B4473783D03Q49836712-BAE69FE6-4D3C-44F4-98FC-BB1B95421386Q50083626-FD5602B2-E916-4072-B06C-480F151DBC00Q50881880-C702BAA3-3FB8-490A-9090-324C91B0B8F8Q51058133-87AC306F-82B6-4FDD-ADD0-745F29F81C58Q52589267-71CB869B-CBBD-4D4F-A888-2F8530ADA67BQ52664962-48B636CB-5C4C-49A0-BAD0-EB70F5153543Q52985095-76779C87-7670-48A4-8E63-48F5E5A49C37Q52996168-0B0E4A98-E7A8-47C0-8859-37A825F22F5CQ53132955-6BB630F6-4FC1-4A14-A66B-4BC1CBA6CB8AQ53505313-2AB2796E-97A7-4D83-B290-1FEF95BE8F8BQ53772593-6234AFA8-1259-4F38-B9E3-E997A3CE4E72Q56352591-D2829332-3B9A-44BB-A2D6-A5BF9DCA50E6Q56359100-7C660B9B-1814-46F5-A8D6-836629AE3389Q56379286-912A75DD-BB84-4B41-8CF8-D13421D4D5A3Q56379991-4A2886E3-6F14-423A-A8B5-0BC5787992EBQ56383213-402D642C-470A-4122-B0BA-21BB2A854892
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Ceci
@ast
Francesco Ceci
@en
Francesco Ceci
@es
Francesco Ceci
@nl
Francesco Ceci
@sl
type
label
Francesco Ceci
@ast
Francesco Ceci
@en
Francesco Ceci
@es
Francesco Ceci
@nl
Francesco Ceci
@sl
prefLabel
Francesco Ceci
@ast
Francesco Ceci
@en
Francesco Ceci
@es
Francesco Ceci
@nl
Francesco Ceci
@sl
P1053
L-2605-2016
P106
P1153
55769083100
P21
P31
P3829
P496
0000-0001-9785-5248